相关临床试验
111
11 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
3
2.7%
已完成
64
57.7%
Enrolling By Invitation
3
2.7%
No Longer Available
1
0.9%
尚未招募
5
4.5%
招募中
16
14.4%
终止
9
8.1%
Unknown
2
1.8%
撤回
8
7.2%
暂无批准数据
- OpenAI's latest free model, GPT-5.5 Instant, scored better than physician-written answers on HealthBench, a benchmark developed with over 260 physicians to evaluate AI health capabilities. - More than 230 million people globally use ChatGPT for health and wellness queries weekly, making healthcare one of OpenAI's most important verticals according to health strategy lead Nate Gross. - A Nature Medicine study of ChatGPT Health found it failed to recommend hospital visits when medically necessary in over half of cases, though OpenAI disputed the methodology. - OpenAI has partnered with eight major health systems including Cedars-Sinai and HCA Healthcare, while Labcorp launched an AI-powered app using OpenAI's models for lab result interpretation.
- A peer-reviewed study shows the Parsortix platform can detect ADC-relevant targets TROP-2 and FRα on circulating tumor cells from TNBC and ovarian cancer patients. - TROP-2 was detected on CTCs with low EpCAM expression, which conventional capture platforms would miss, highlighting Parsortix's technical differentiation. - PD-L1 was simultaneously detectable alongside TROP-2 on the same CTCs in the same workflow, supporting combination immunotherapy monitoring. - The study addresses an unmet need for minimally invasive, real-time biomarker monitoring in the rapidly growing $17 billion ADC therapeutic market.
- UNC Health has submitted a Certificate of Need application to North Carolina DHHS for a 92-bed hospital near downtown Asheville, with a hearing scheduled for August and a final decision expected in December. - The proposed Asheville facility would offer emergency care, intensive care, neonatology, cardiology, gastroenterology, radiology, psychiatry, and other specialty services on a 21.5-acre site near Westgate Mall. - UNC Health also unveiled plans for a new community hospital in Wilmington on a 62-acre site at South 17th Street and Shipyard Boulevard, targeting a 2030 opening date pending regulatory approvals. - Both proposals aim to address growing regional demand and provide more healthcare choice, with UNC Health CEO Dr. Cristy Page emphasizing the goal of delivering "care closer to home."
- PSMA PET imaging has revolutionized prostate cancer detection and management, particularly in biochemical recurrence settings, with multiple FDA-approved agents now available including gallium-68 PSMA-11, piflufolastat F 18, and flotufolastat F 18. - The newer agent flotufolastat F 18 offers unique advantages in postprostatectomy recurrence scenarios due to its reduced bladder activity, allowing better visualization of potential recurrence in the prostate bed. - While PSMA PET has largely replaced fluciclovine F 18, the metabolic tracer still maintains a role in specific scenarios including tumors with low PSMA expression and neuroendocrine differentiation cases. - Expert panels emphasize that agent selection often depends on institutional availability and specific clinical contexts, as detection rates and sensitivity remain comparable between different PSMA PET tracers.
